We are live on ! Find out more
DFTX

Definium Therapeutics
DFTX

93 hedge funds and large institutions have $12.1M invested in Definium Therapeutics in 2023 Q3 according to their latest regulatory filings, with 19 funds opening new positions, 20 increasing their positions, 12 reducing their positions, and 9 closing their positions.

New
Increased
Maintained
Reduced
Closed

500% more call options, than puts

Call options by funds: $6.01M | Put options by funds: $1M

111% more first-time investments, than exits

New positions opened: 19 | Existing positions closed: 9

67% more repeat investments, than reductions

Existing positions increased: 20 | Existing positions reduced: 12

11% more funds holding

Funds holding: 84 → 93 (+9)

0% more funds holding in top 10

Funds holding in top 10: 1 → 1 (0)

0.32% less ownership

Funds ownership: 10.08% → 9.76% (-0.32%)

13% less capital invested

Capital invested by funds: $13.9M → $12.1M (-$1.75M)

Holders
93
Holders Change
+9
Holders Change %
+10.71%
% of All Funds
1.48%
Holding in Top 10
1
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
0.02%
New
19
Increased
20
Reduced
12
Closed
9
Calls
$6.01M
Puts
$1M
Net Calls
+$5M
Net Calls Change
-$4M

Top Buyers

Rank Fund Capital Flow
1
Susquehanna International Group
Susquehanna International Group
Pennsylvania
+$797K
2
Millennium Management
Millennium Management
New York
+$785K
3
Citigroup
Citigroup
New York
+$358K
4
Group One Trading
Group One Trading
Illinois
+$347K
5
Citadel Advisors
Citadel Advisors
Florida
+$254K

Top Sellers

Rank Fund Capital Flow
1
Alyeska Investment Group
Alyeska Investment Group
Illinois
-$2.85M
2
BB
Busey Bank
Illinois
-$156K
3
Renaissance Technologies
Renaissance Technologies
New York
-$130K
4
FCH
Freestone Capital Holdings
Washington
-$41K
5
BlackRock
BlackRock
New York
-$17.4K
Name Holding Trade Value Shares
Change 		Change in
Stake
HWM
76
HighMark Wealth Management
Minnesota
$88 -$4 -1 -3%
AAP
77
Arax Advisory Partners
Colorado
$88 – – –
RF
78
Robbins Farley
New Hampshire
$88 +$115 +28 New
AWM
79
Avior Wealth Management
Nebraska
$75 – – –
PP
80
Pacifica Partners
Canada
$62 – – –
GI
81
Gradient Investments
Minnesota
$56 – – –
VAG
82
VisionPoint Advisory Group
Texas
$50 +$66 +16 New
SIC
83
SJS Investment Consulting
Ohio
$44 – – –
JWM
84
Janiczek Wealth Management
Colorado
$32 – – –
CB
85
CNB Bank
Pennsylvania
$31 – – –
FWM
86
Focused Wealth Management
New York
$31 – – –
HI
87
Harbour Investments
Wisconsin
$31 – – –
GEA
88
Glen Eagle Advisors
New Jersey
$19 -$99 -24 -80%
BC
89
Belmont Capital
California
$19 – – –
AF
90
Advisornet Financial
Minnesota
$9 – – –
HNB
91
Huntington National Bank
Ohio
$1 – – –
Alyeska Investment Group
92
Alyeska Investment Group
Illinois
– -$2.85M -796,962 Closed
Renaissance Technologies
93
Renaissance Technologies
New York
– -$130K -36,519 Closed
FCH
94
Freestone Capital Holdings
Washington
– -$41K -11,497 Closed
MFT
95
Moisand Fitzgerald Tamayo
Florida
– -$7.14K -2,000 Closed
CWA
96
Clearview Wealth Advisors
Oregon
– -$236 -66 Closed
Northwestern Mutual Wealth Management
97
Northwestern Mutual Wealth Management
Wisconsin
– -$118 -33 Closed
NC
98
NewSquare Capital
Pennsylvania
– -$61 -17 Closed
AssetMark Inc
99
AssetMark Inc
California
– -$29 -8 Closed
HS
100
Horan Securities
United States
– -$7 -2 Closed
1 2 3
4

DFTX Hedge Fund Activity: Q3 2023 in Review

93 of the 6,301 institutional investors tracked by Wall St. Rank reported a position in Definium Therapeutics (DFTX) for Q3 2023, worth a combined $12.1M — down 13% from $13.9M a quarter earlier.

Buyers outnumbered sellers: 19 funds opened new DFTX positions and 9 closed out — a net gain of 10 holders — while 20 added to existing stakes and 12 trimmed.

The largest buyer was Susquehanna International Group, opening a new position worth an estimated $797K. The largest seller was Alyeska Investment Group, exiting entirely with an estimated $2.85M sold.

  • 93 institutional investors held Definium Therapeutics (DFTX) as of Q3 2023, up from 84 in Q2 2023.
  • Funds reported $12.1M of Definium Therapeutics stock for Q3 2023, down 13% quarter-over-quarter.
  • 19 funds opened new Definium Therapeutics positions in Q3 2023 and 9 closed out, a net change of +10 holders.
  • The largest Definium Therapeutics buyer in Q3 2023 was Susquehanna International Group, an estimated $797K added.
  • The largest Definium Therapeutics seller in Q3 2023 was Alyeska Investment Group, an estimated $2.85M sold.

Based on aggregated 13F filings for Q3 2023.